Adding the drug Herceptin to chemotherapy for certain breast cancer patients increases overall survival and reduces the risk of recurrence compared to chemotherapy alone, new research shows. The study found that adding a year of Herceptin (trastuzumab) to standard chemotherapy improved overall survival by 37 percent.

The addition of Herceptin also boosted 10-year overall survival rates from 75 percent to 84 percent. And the 10-year disease-free survival rate went from 62 percent to 74 percent for those also taking Herceptin, the study found.

READ FULL ARTICLE Curated publisher From Medical Express